Fewer participants treated with SNG001 compared to placebo progressed to hospitalisation (1/110 vs 7/110, P=0.07) SNG001 was well-tolerated with a favourable safety profile consistent with
Synairgen announces positive data from the US NIH-led ACTIV-2 Phase 2 trial for SNG001 in home-based participants with COVID-19 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Monkeypox Is A Different Drug Development Ballgame From COVID-19 informa.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from informa.com Daily Mail and Mail on Sunday newspapers.
The UCLA Clinical AIDS Research and Education (CARE) Center today announced its participation in STOMP (Study of Tecovirimat for Human Monkeypox Virus), or A5418, a phase 3, randomized, placebo-controlled, double-blind trial evaluating the safety and efficacy of tecovirimat for the treatment of human monkeypox.